Evolus Inc
2 nominees · 3 ballot items.
Election of two Class II directors (Brady Stewart and Vikram Malik); ratification of Ernst & Young LLP as independent auditor for 2026; and an advisory (non-binding) vote to approve the compensation of the Company’s named executive officers (say-on-pay).
Follow how the vote landed and what changed on Evolus Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot3
- 1
Election of Class II Directors: Brady Stewart and Vikram Malik
ManagementBoard: FORElect Brady Stewart and Vikram Malik as Class II directors to serve until the 2029 annual meeting and until their successors are duly elected and qualified.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm for 2026
ManagementBoard: FORRatify the audit committee’s appointment of Ernst & Young LLP as Evolus’ independent registered public accounting firm for the year ending December 31, 2026.
- 3
Advisory Approval of Named Executive Officer Compensation (Say-on-Pay
ManagementBoard: FORNon-binding advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
More detail
This proposal asks stockholders to cast an advisory (non-binding) vote approving the Company’s executive compensation disclosures and overall pay program for its named executive officers. Management and the board seek shareholder endorsement to affirm their pay-for-performance philosophy and to signal continuing support for compensation design, which relies heavily on long‑term equity (RSUs, PRSUs and options) and performance-based bonuses tied to revenue and non‑GAAP operating profit; the proxy discloses that a substantial portion of NEO compensation is ‘at risk’ and that the compensation committee engaged an independent consultant (Radford) and used a peer group to set pay. The proxy also documents that the committee adjusted 2025 incentive goals mid-year in response to market conditions—reducing maximum payout and resetting revenue thresholds—and applied negative discretion to lower final annual cash payouts from a 60% formulaic result to a 55% actual payout, demonstrating active oversight of payouts. The board emphasizes governance safeguards such as an independent compensation committee, a clawback policy, prohibitions on pledging and hedging, and limits on option repricing, which it cites in recommending a FOR vote. From an analyst perspective, the material questions include whether the equity-heavy structure and multi-year performance metrics sufficiently align management and shareholder interests given mid-year target resets and negative discretion application, and whether disclosed protections (clawback, independent consultant, committee composition) mitigate risk of excessive risk-taking. The advisory vote is non-binding, so a FOR result would be a signal of shareholder support but would not legally constrain future compensation decisions; conversely, a negative vote would likely prompt the compensation committee to reassess program design. Company‑specific context relevant to evaluation includes the Company’s 2025 revenue results (approximately $297.2 million), the use of PRSUs with two-year revenue/non‑GAAP profit goals, a recent history of strong shareholder support for say-on-pay (approx. 96% approval in 2025), and the committee’s demonstrated willingness to exercise discretion. Overall, the proposal centers on validating the compensation framework that the board argues aligns pay with performance, while investors should weigh the trade-offs of significant equity grants, multi-year and market-resettable targets, and the non-binding nature of the vote when assessing governance quality and alignment.
Nominees on the ballot2
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | 9.7% | 6,376,857 | $26M |
| 2 | BRAIDWELL LP | 4.7% | 3,105,209 | $13M |
| 3 | Frazier Life Sciences Management, L.P. | 4.0% | 2,630,665 | $11M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 2,470,408 | $10M |
| 5 | Soleus Capital Management, L.P. | 3.4% | 2,245,360 | $9M |
| 6 | BlackRock, Inc. | 3.3% | 2,172,627 | $9M |
| 7 | Stonepine Capital Management, LLC | 2.7% | 1,759,091 | $7M |
| 8 | BlackRock, Inc. | 2.5% | 1,615,588 | $7M |
| 9 | MILLENNIUM MANAGEMENT LLC | 2.2% | 1,461,159 | $6M |
| 10 | ARMISTICE CAPITAL, LLC | 2.1% | 1,396,000 | $6M |
Other Healthcare sector meetings6
Upcoming shareholder meetings at Evolus Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the Evolus Inc 2026 annual meeting?
- Evolus Inc (EOLS) holds its 2026 annual shareholder meeting on Thursday, June 11, 2026.
- What is the record date for the Evolus Inc 2026 meeting?
- The record date for the Evolus Inc 2026 meeting is Tuesday, April 14, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Evolus Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Evolus Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Evolus Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Evolus Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.